Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $748000.0.

  • Relay Therapeutics' Depreciation & Amortization (CF) fell 4528.16% to $748000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 2203.45%. This contributed to the annual value of $5.5 million for FY2024, which is 370.09% up from last year.
  • Latest data reveals that Relay Therapeutics reported Depreciation & Amortization (CF) of $748000.0 as of Q3 2025, which was down 4528.16% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Depreciation & Amortization (CF) ranged from a high of $1.4 million in Q1 2024 and a low of $748000.0 during Q3 2025
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $1.2 million (2022), whereas its average is $1.1 million.
  • As far as peak fluctuations go, Relay Therapeutics' Depreciation & Amortization (CF) soared by 3953.97% in 2023, and later crashed by 4528.16% in 2025.
  • Relay Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $1.0 million in 2021, then rose by 12.77% to $1.2 million in 2022, then rose by 17.92% to $1.4 million in 2023, then decreased by 2.98% to $1.3 million in 2024, then crashed by 43.93% to $748000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $748000.0 for Q3 2025, versus $1.0 million for Q2 2025 and $1.2 million for Q1 2025.